REVISOR

17-2080

This Document can be made available in alternative formats upon request

State of Minnesota

## HOUSE OF REPRESENTATIVES NINETIETH SESSION H. F. No. 808

02/06/2017 Authored by Zerwas, Hamilton, Loeffler and Freiberg The bill was read for the first time and referred to the Committee on Health and Human Services Reform

1.1	A bill for an act
1.2 1.3 1.4	relating to human services; allowing the early periodic screening, diagnosis, and treatment program to cover stiripentol; amending Minnesota Statutes 2016, section 256B.0625, subdivision 64.
1.5	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
1.6	Section 1. Minnesota Statutes 2016, section 256B.0625, subdivision 64, is amended to
1.7	read:
1.8	Subd. 64. Investigational drugs, biological products, and devices. Medical assistance
1.9	and the early periodic screening, diagnosis, and treatment (EPSDT) program do not cover
1.10	costs incidental to, associated with, or resulting from the use of investigational drugs,
1.11	biological products, or devices as defined in section 151.375, except that stiripentol may
1.12	be covered by the EPSDT program for an eligible enrollee with a documented diagnosis of
1.13	Dravet syndrome, for whom all other available covered prescription medications for Dravet
1.14	syndrome have been exhausted. Stiripentol may only be covered if the United States Food
1.15	and Drug Administration has approved the treating physician's individual patient
1.16	investigational new drug application (IND) for the use of stiripentol for treatment or
1.17	emergency use.